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Tubercle bacilli and  a  variety of crude fractions derived from them have 
long been known to be capable of activating the immunological reactivity of 
higher  animals.  The  homologous  and  heterologous  antimicrobial  immuno- 
genicity of one such  fraction,  a  methanol-insoluble residue  of phenol-killed, 
acetone-washed  bacilli  of  the  BCG  strain,  has  been  described  in  previous 
communications (1,  2),  and it was pointed out  (2)  that this material  (which 
will be referred to as MER in this and succeeding papers) possesses a number of 
distinct advantages over living BCG and other hitherto described fractions as a 
heterologous  immunogen:  MER  is  nonliving,  very  stable  to  chemical  and 
physical manipulations,  and predictably effective under defined experimental 
conditions;  its  homologous  and  heterologous  immunogenicity is  at  least  as 
great as,  and  in many instances  greater than,  that  of living BCG; it is  not 
toxic systemically in quantities several times larger than the optimally immu- 
nogenic mounts, and it is well tolerated by tissues locally; and it induces only 
a low degree of tuberculin hypersensitivity. 
The mode of action of the MER remains to be determined, but it has already 
been shown to exert profound effects on the anatomy and physiology of the 
reticuloendothelial system,  and  on  immunological  responsiveness  to  specific 
antigenic stimuli  (3). These broad immunological propensities of the fraction 
encouraged an investigation of its possible efficacy in heightening the resist- 
ance of animals to neoplastic cells. This investigation was based on the follow- 
ing premise" 
The morphology and  physiology of neoplastic cells differ,  sometimes  markedly, 
from those of corresponding  normal tissue.  Such differences in appearance and be- 
havior are not unlikely to reflect changes in the structure and arrangement of macro- 
* This work was supported by Research Grants AI-2309 and CA-05388 from the United 
States Public Health Service; E-292 and E-344 from the American Cancer Society; and by 
Cancer Research Funds of the University of California. 
1039 1040  HETEROLOGOUS IMM'UNOGENICITY. II 
molecular cell components, and it is well recognized that even relatively minor changes 
in macromolecular composition or organization can result in new antigenic properties. 
It is not unreasonable to expect, therefore, that neoplastic cells may carry antigenic 
determinants  acquired in  the course of the neoplastic transformation,  and not pos- 
sessed by the normal cells of the individual. 
Support  for this  expectation  comes from  the  repeated  demonstrations  in  recent 
years that many of the neoplasms studied in the laboratory do, indeed, have antigenic 
characteristics specific to the neoplastic condition or specifically associated with the 
presence of oncogenic viruses. This has been shown for tumors induced experimentally 
by chemical carcinogens (4-9), developing at the site of implantation of cellophane 
films (10), or initiated by the polyoma (11,  12), Rous sarcoma (13), and certain murine 
leukemogenic  viruses  (14-19).  The  tumor-associated  antigenicity  of  spontaneous 
mammary carcinomas of mice, first indicated by Hirsch et al. (20), has now also been 
established (21-29). 
The failure of an animal to reject its own, but antigenically foreign, tumor cells 
would, therefore, seem to demand an immunological explanation. Such an explanation 
has been advanced  by several investigators  (e.g.  reference 30)  who suggest  that a 
major function of the homograft reaction may be the eradication of neoplastic mu- 
tants, and that progressive neoplasia occurs, accordingly, only in animals suffering a 
preexisting immunological disability.  This hypothesis is supported  by observations 
which point to an inverse association between susceptibility to neoplastic disease and 
immunological ability as manifested by antibody synthetic activity (31,  32), allergic 
disease  (33),  homograft reactivity (34),  and  reticuloendothelial phagocytic function 
(35, 36). 
It would follow from this consideration that agents which act as powerful stimu- 
lators of immunological reactivity might also enable an animal to cope more sucess- 
fully, by immunological means, with its indigenous neoplastic cells. 
When the present investigation  was begun,  it had already been reported by 
Old et al.  that  infection  with  living BCG increased  the  resistance  of mice to 
transplants  of several  nonisogenic,  laboratory-adapted  cultures  of neoplastic 
cells  (37).  This activity of BCG was subsequently  confirmed in isogenic host- 
tumor  systems  by Old  et  al.  (38)  and  Weiss  et al.  (39).  Preliminary  studies 
with  the  MER  fraction  revealed it to be generally more effective than living 
BCG  in  evoking  a  degree  of  heightened  resistance  to  isogenic  tumors  (39). 
The  present  communication  describes  the  results  of  further  studies  of  the 
ability  of the  MER  fraction  to  heighten  host  resistance  against  isografts  of 
spontaneous  and  induced  cancers  of  mice. 
Materials and Methods 
Methanol Extraxtion Residue and BCG.--The preparation of cultures of living BCG and of 
the MER fraction has been described previously  (2). 
Anlmals.--The experiments  were carried  out with young adult (10- to 15-wk-old) inbred 
mice of the BALB/c, C3H, C3ttf,  RIII, A, DBA/2, and C57B1 strains,  derived  from the 
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in Berkeley. Animals were distributed randomly among the several experimental groups  in 
each experiment and were maintained on a  diet of standard mouse pellets and water ad lib. 
It is crucial that animals employed in experiments designed to detect immunological reac- 
tions specifically directed at tumor-associated antigens be isogenic with the tumor donors. The 
operative isogenlcity  I of the mouse strains used in this study is evident from two categories of 
observation: intrastrain transplants of ovarian, pituitary, adrenal, and mammary tissues are 
performed continually at the Cancer Research Genetics Laboratory, and these tissues are well 
accepted upon second as weLl as upon first exposure; and, reciprocal first and second set skin 
grafts exchanged between randomly selected pairs of control animals of the same sex  from 
each strain throughout the course of this study provided no indication of isoantigenic con- 
tamination of the strains. 
TumoTs.--The  tumors used had arisen spontaneously in isogenic animals at the Cancer 
Research  Genetics Laboratory or were induced by exposure  to chemical carcinogens. The 
tumors were identified by histological examination, carried out by Dr. K. B. DeOme of the 
Laboratory, and were maintained by serial passage in isogenlc tumor bank hosts. 
Tumor Implant~tion.--Tumors  were removed surgically from the tumor bank hosts im- 
mediately before they were to be used. Necrotic and sinusoidal tissue was trimmed away, and 
the remaining neoplastic tissue was cut with a razor blade into fragments of either 0.5 to 1.0 
or 0.05 to 0.1 mm  8. In order to prevent drying of the tumor tissue during manipulation, the 
tissue was flooded with tissue culture medium 199. The smaller pieces were selected for ap- 
propriate size by floating them over an ocular micrometer and making the selection under a 
dissecting microscope. Although considerable care was thus taken to assure that all the animals 
in any one experiment were challenged with tumor implants of nearly equal size, it is not 
certain that the number of living cells introduced at each chaLlenge  site was roughly equal. 
This is because only a small proportion of the cells in a tumor fragment or, for that matter, in 
a suspension of tumor cells, is likely to survive the implantation procedure, and it is probable 
that this proportion varies from aLiquot  to aliquot and from one animal to the next. On the 
other hand, such differences could be expected to be distributed equally among animals of the 
various treatment groups in any one experiment. It has also been shown (40)  that variation in 
measured tumor (mammary carcinoma) implant volume over a  2-log range, 0.06 to 6.0 mm  s, 
had no significant effect on the times of appearance of palpable tumors or on their subsequent 
growth rates. 
Implantation was either with the larger tumor pieces inserted subcutaneously along the 
flanks of the animals by means of a trocar, or with the smaller pieces placed surgically into the 
inguinal mammary fat pads. The latter technique has been described elsewhere (22). 
The  animals were  observed periodically  after  tumor  implantation for  development  of 
palpable tumors. The growth of the tumors was followed by periodic caliper measurements of 
the two diameters evenly bisecting the neoplasms at right angles to each other. The same 
observer always read the tumors in any one experiment, to avoid individual variations in 
assessment of tumor size. 
Growth of the tumors is expressed in terms of increments of the calculated tumor volumes. 
Tumor volumes were calculated from the formula V --  (0.4) (ab2), where V ffi volume; a and 
1 Complete homogeneity of a  multichromosomal spedes is probably not attainable. The 
term "isogenleity"  has only a  limited, operative meaning: a  suifieient degree of isoantigenic 
similarity, developed by repeated brother-sister matings, to permit the permanent acceptance 
of second set tissue grafts (skin is the tissue usuaLly  considered to be the most sensitive in 
detecting slight manifestations of homograft activity). Such isogenicity is adequate for experi- 
ments whose object it is to detect immunological reactions directed at antigens not possessed 
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b are the major and minor tumor diameters, respectively, as measured in the intact animal; 
and 0.4 is a constant derived from the relationship of values a and b of 121 spontaneous mam- 
mary carcinomas to their actual saline displacement volumes (41). As pointed our previously 
(41),  expression of tumor growth as increments in tumor volumes provides a  more accurate 
estimate of actual tumor mass increase than is obtained by a consideration of increments of 
tumor diameters. 
RESULTS 
Effect  of Pretreatment with MER on Acceptance of Skin Isografls.--Although 
animals  of the  inbred mouse strains  employed in  this  study were shown  to 
accept skin isografts permanently and  with no apparent  evidence of even a 
transient  homograft  reaction,  a  slight  residual  heterozygosis of isoantigenic 
TABLE I 
Effect of Pretreatment  of C3H and A  Mice with MER on the Acceptance  of First Skin Isografts 
Pretreatment with  No. of animals 
Isografts  Autografts 
No. of technical  failures  No. of rejections[ No. of technical  failures  No. of rejection., 
Saline  19  1  1  (?)*  0  1  (?)* 
MER~  19§  1  0  2  I  (?)* 
* Graft rejection may have resulted from technical failure. 
:~ 0.5 mg injected intraperitoneaUy 2 to 6 wk prior to grafting. 
§ Reciprocal isografts of body skin were exchanged between 10  pairs of young  (3  to 6 
months old) C3H and 10 pairs of young A females. Autografts were also performed on each 
animal to provide procedure controls. The animals were observed for 4 to 12 months. 1 C3H 
animal was lost in each group immediately after the grafts were performed. 
characteristics could have remained undetected. The possibility that reactivity 
to  such  heterozygosis might  be  enlarged  by treatment  of the  animals  with 
MER had to be ruled out in order to assure that any effects of MER on the 
fate of tumor implants could not be ascribed to this artifact.  2 
To this end, half of all the animals on which routine skin grafts were performed as  iso- 
genicity checks throughout the course of this study were pretreated with 0.5 mg of the MER 
2 to 6 wk before reciprocal skin grafts were exchanged. The animals were examined 3 to 5 
times weekly following the removal of the bandages 1 wk after grafting. 
The effects of MER pretreatment on the acceptance of first set reciprocal body skin grafts 
exchanged between 10 pairs of strain A and 10 pairs of C3H mice are shown in Table I. Half 
the pairs were pretreated with MER, the other half with saline.  Autografts were performed 
on every animal as well, to control for technical failure. 
2  It has already been found that pretreatment with MER will increase homograft reactivity 
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It is  seen from Table I  that MER pretreatment did not affect skin graft 
acceptance. The few failures to take could  be ascribed to technical difficulty 
in every instance---loss of bandage, infection, removal of the graft as a  result 
of scratching--and they occurred no  more often among isografts than among 
the autografts.  The appearance of the surviving isografts throughout the ob- 
servation periods  of 4  to  12  months was  indistinguishable  from that  of the 
autografts,  regardless  of  the  animals'  pretreatment. 
At the end of the observation period,  the surviving animals received a  sec- 
ond body skin graft, from the same donors  where these were available,  and 
from a  randomly selected isogenic female where the other member of a  pair 
had been lost. These second set grafts were accepted as well as the first ones, 
and,  again,  no evidence of an MER effect could be discerned.  It seems safe 
to assume, therefore, that any effects displayed by the MER against neoplastic 
tissue  implants are directed at  tumor-associated  components  of  such  tissue. 
Effect of Prelreatmenl with MER and Other BCG Preparations on Acceptance 
of Isografls  of a  Spontaneous  Uterine Sarcoma  in BALB/c Mice.-- 
BALB/c females received single intraperitoneal injections of one of the following in 0.5 
cc: living BCG; intact phenol-killed BCG; a methanol extract of phenolized BCG; MER; or 
saline. Different quantities of the tubercle bacillus preparations were given. The animals were 
challenged 2, 4, or 12 wk later with two subcutaneous implants each of a spontaneous uterine 
sarcoma. This tumor had arisen 2 yr previously, and was in the 15th transplant generations 
when employed in  the present  study.  The  animals were observed for the development of 
progressively growing tumors and were retained in the experiment until several weeks after 
all control mice in each challenge interval group had developed at least one tumor  (only 1 
control animal remained tumor-free 4 months after challenge). The results are shown in Table 
II. 
It is seen from Table II that only 1 of 27  saline-treated controls failed to 
support at  least one progressively growing tumor.  In contrast, many of the 
animals  treated  with  the  BCG  preparation  remained  free  of  tumors.  Pre- 
treatment with living BCG did not appear to be as effective as pretreatment 
with the bacillary fractions. 0.5 nag of MER protected 4 of 5 animals challenged 
4  wk  after vaccination,  but  larger quantities  were ineffective in  preventing 
growth of tumors from transplants  implanted at  any of the three intervals. 
The  longer  vaccination-challenge  intervals  appeared  to  be  more  favorable 
for the manifestation of increased resistance. Thus, treatment with 1.5 nag of 
intact phenolized bacilli  evoked effective resistance  in  only 1  of  10  animals 
challenged 2 wk later, but protected 7 of 9 animals implanted with the tumor 
12 wk after treatment. When all the treatment groups are considered together, 
it  is  seen that  21/87  animals  resisted  tumor  challenge,  but  that,  of the  28 
challenged after only 2  wk,  all but one developed tumors. 
It has been observed in this laboratory that periods of time as long as  11 
months sometimes elapse before palpable tumors appear at the site of implan- 1044  HETEROLOGOUS  IM~'UNOGENICITY.  II 
tation with small numbers of tumor cells (43).  In the present instance, mice 
were  held  for only several weeks  after tumors  had  appeared  in  the  control 
animals.  In  order  to  ascertain  whether  failure  of  tumor  appearance  in  the 
apparently protected animals  reflected complete destruction of the  implants, 
or only an increased lag period of their growth, many of the animals grossly 
free of tumors at  the termination of the experiment were  autopsied and ex- 
amine& In most instances, no evidence of growing neoplastic tissue was seen. 
TABLE  II 
Effect  of Pretreatment of BALB/c Mice with Various  BCG Preparations  on the Acceptance of 
Isografls of a Spontaneous  Uterine Sarcoma 
Pretreatment in 0.5 cc, i.p. with: 
Living BCG, 1:10 dilutions 
Living BCG, 1:50 dilution 
Phenolized BCG,§ 1.0 mg 
Phenolised BCG, 1.5 mg 
Methanol extract,§ 1.0 mg 
MER,II 0.5 mg 
MER,  1.0 mg 
MER,  1.5 mg 
All treatment groups combined 
Saline (controls) 
Proportion of animals remaining tumor-free* when 
treatment-tumor challenge  interval was: 
2 wk  4  wk 
--  2/7 
0/9 
--  3/6 
1/lO 
--  317 
--  4/s 
--  0/7 
0/9 
1/28  12/32 
1/lO  0/7 
12  wk 
1/8 
7/9 
0It0 
8/27 
o/1o 
* The animals were observed for 2 to 4 months after challenge. Animals dying from ex- 
traneous causes before the termination of the experiment are not included in the table. 
Living 7-day-old cultures of BCG in Dubos Tween broth were diluted 1:10 and 1: 50 in 
sterile saline. 
§ The preparation of intact phenol-killed BCG and of a  methanolic extract derived from 
them has been described previously (1). 
[] MER, methanol extraction residue. 
In some animals, no trace of the initial implants could be found; in others, the 
tumor implants could be detected, but these had usually grown only a  little, 
were not  vascularized,  and did  not appear  to  be composed of viable tissue. 
In only a  few mice scored as tumor-free upon palpation was there indication 
that  significant growth  of  the implants  had  occurred. 
In order to ascertain whether treated animals resistant to a  first tumor challenge would 
display similar resistance upon a second, more stringent challenge, 6 of the 7 mice which had 
been given 1.5 mg of phenolized BCG and which had failed to develop tumors when challenged 
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challenge took place 4 months after the first (i.e. 7 months after treatment), with one sub- 
cutaneous implant each of larger fragments of the tumor, 1 to 2 mm  8. A control group of 15 
BALB/c males was similarly challenged. The animals were observed for 80 days after chal- 
lenge. The results are shown in Table III. 
As  seen  from  Table  III,  none  of  the  6  rechallenged animals  developed a 
tumor, while all of the 15 controls did. 
It should be noted that some of the animals treated with MER  which none- 
theless permitted growth of the cancer implants still exhibited a  delayed onset 
of this growth, or a  retardation of its rate, or lived significantly longer despite 
their  tumors  than  did the  control animals.  It  was  not possible in all experi- 
ments to bestow complete protection against the uterine sarcoma on a  signifi- 
cant proportion of treated animals, but some evidence of the protective efficacy 
of pretreatment with the MER  and with other BCG preparations was always 
clearly discernible against this tumor. 
TABLE  III 
Effevt of Pretreatment  of BALB/c M~e with 1.5 rag Phenol-Killed BCG on the Acceptance of a 
Second Isografl  of a Spontaneou~  Uterine Sarcoma  7 Montks Later 
Pretreatment in 0.5 cc, i.p. with:  Proportion of animals remaining tumor-free* 
Untreated controls  0115 
Phenolized BCG, 1.5 mg:~  6/6§ 
* The animals were observed for 80 days after challenge. 
Vaccination was 7 months previously; first tumor challenge was 12 wk after vaccination. 
§ The animals were autopsied at termination of the experiment; in none was tumor tissue 
found. 
Effect of Treatment with MER and Other BCG Preparations  on the Growth 
of Established Implants  of the  Uterine Sarcoma in BALB/c  M/ce.--Two  ex- 
periments  were  conducted  to  ascertain  the  efficacy of  tubercle  bacillus sub- 
stances against transplants of the uterine sarcoma established simultaneously 
with, or prior to, treatment. 
Experiment 1: 
BALB/c females were given two intraperitoneal injections of one of the following: saline; 
a  1:10 dilution of a 7-day-old BCG culture; or, 0.25 or 0.5 nag of the MER. Each injection 
was in 0.5 cc of saline. 9 or 10 animals were employed in each group. The first injection was 
administered on the day of implantation of the uterine sarcoma, the second injection 6 days 
later. Tumor challenge was by a single implant, placed subcutaneously.  The animals were 
observed for 40 days. 
The support given by the differently treated animals to growth of the tumor isografts is 
shown diagrammatically  in Table IV. 
It is common to find a wide range of variation in the rapidity of development 
of tumors  growing from implants of recently arisen neoplasms, and this was t..~ 
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the case in the present experiment. The data are therefore presented by giving 
the size of each tumor in each animal at several intervals after challenge, thus 
showing the different patterns  of tumor size  distribution.  The significance of 
these  differences relative  to  the  saline-treated  controls  was analyzed by the 
nonparametric Mann-Whitney distribution-free test (44). 
It  is  seen  from  Table  IV that  almost  all  the  tumor  implants  developed 
progressively, regardless of the treatment of the animals.  However, there was 
some retardation of the rate of tumor development in the animals given 0.25 
mg of MER. The degree of retardation was significant at the 0.1 but not quite 
at the 0.05 level. 
Experiment 2: 
The plan of this experiment was identical to the preceding one, except that treatment of 
the animals was administered 6 and 13 days after implantation of the tumors. The results are 
depicted in  Table V. 
It is seen from Table V  that most of the tumor implants again developed, 
and that treatment of the animals with 0.5 mg of MER, but not with 0.25 rag, 
retarded  their  growth significantly.  The  requirement  for the  larger  quantity 
of MER to effect retardation  of tumor growth in  this experiment may have 
been due to the fact that treatment was not initiated until 6 days after tumor 
implantation, and that a  stronger stimulation of the immunological apparatus 
of the animals was,  therefore,  required  to bring about a  degree of tumor in- 
hibition. 
The  failure  of  the  tubercle  bacillus  substances  to  prevent  tumor  growth 
entirely when administered  simultaneously with,  or after,  the  tumor implan- 
tation could well reflect the necessity of stimuiating immunological responsive- 
ness  some  time  before challenge  in  order  to  obtain  complete  protection.  It 
could also be due to the fact that administration by multiple injections con- 
stitntes a supra-optimal stimulation. The narrowness of the optimum dosage of 
MER  in  antimicroblal  protection  experiments  has  already  been  indicated 
(2);  the  similar  importance  of dosage  in  antitumor  systems  will  be  further 
documented  in  the  following  experiments. 
Effect  of Pretreatment with MER and Living BCG on the Growth of Isografts 
of a ttepatoma Arising in C3tt Mice Treated with Carbon Tetractdoride.-- 
C3H males were given single intraperitoneal injections of one of the following  in 0.5 cc of 
saline: living BCG; 0.25 or 0.5 mg of MER; or saline only. The animals were challenged 2 or 
4 wk later with a single subcutaneous implant of a hepatoma which had arisen 5 yr previously, 
and had been transplanted every 2 to 3 wk. 8 to 10 animals were included in each group. The 
animals were observed for 2 to 3 months after implantation of the tumors. The results are 
presented in Tables VIA and VI B. 
It is seen from Tables VI A and VI B that pretreatment of the animals with e3 
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the  smaller  quantity  of  MER,  0.25  mg,  sufficed  to  retard  development  of 
hepatomas  implanted  2  wk  after  administration,  and  that  0.5  mg  of  MER 
was  necessary to  elicit such  an  effect when  4  wk elapsed between  treatment 
and tumor challenge. The significance of dosage of MER  in relation to treat- 
ment-challenge interval is  thus  indicated in  this  as  well as  in  the  preceding 
experiment. 
The  effect of pretreatment  with MER  was also manifested by a  prolonged 
survival of the animals. This is illustrated in Table VI C. 
TABLE VI C 
Survival of C3H Mice Following Implantation of an Isogenic Hepatoma 
No. of  Treatment of animals  animals 
Cumulative No. of animals dead at following  intervals after tumor 
challenge, ok* 
5  ]  6  7  [  8  I  9  I  10  11  12  13 
Treatment-challenge interval: g wk: 
Saline  9  2  6  9  ...... 
Living BCG  9  1  3  6  7  7  8  9  --  -- 
MER, 0.25 mg  8  0  0  0  2  2  3  6  7  8 
MER, 0.5 mg  8  1  2  3  5  5  5  5  6  7§ 
Trealment.challenge intocal:  4 wkll 
Saline  10  0  0  1  3  6  I 4 animals alive, with tumors 
Living BCG  10  3  3  4  7  7  [ 3 animals alive, with tumors 
MER, 0.25 mg  10  0  1  1  3  6  4 animals alive, with tumors 
MER, 0.5 mg  10  0  0  0  2  2  8 animals alive, with tumors 
* All animals had large tumors at death. 
Experiment terminated at 13 wk. 
§ 1 animal alive, with massive tumor, at termination of experiment. 
II Experiment terminated at 9 wk. 
Pretreatment  with living BCG exerted no appreciable effect on  the  course 
of development of the hepatoma isografts. 
Effect of Pretreatment with MER  on the Growth of Isografls  of a Spontaneous 
Mammary Carcinoma in RIII  Mice.-- 
RIII females were given single intraperitoneal injections of 0.5 mg of MER or saline only. 
There were 15 animals in each group. 4 months later, the animals were challenged with two 
intramammary implants each of a first generation  transplant of a mammary adenocarcinoma 
which had arisen spontaneously in a  multiparous RIII breeding female.  The animals were 
observed for 17 wk after implantation. The results are presented in Table VII. 
It is evident from Table VII that administration of the MER  fraction de- 
layed  considerably  the  development  of  the  mammary  tumor  isografts. 1052  ~-ETEROLOGOUS  IMMUNOGENICITY.  II 
Effect of Pretreatment  with ICIER on the Growth of Isografls  of a Spontaneous 
Osteogenic Sarcoma.-- 
C3H males and females were given single intraperitoneal injections of either 0.25  or 0.5 
mg of MER in 0.5 ee of saline, or of saline only. Each group consisted of 20 animals. Half the 
animals in each group were ehallenged 2 wk later with a  single subcutaneous implant of an 
osteogenic sarcoma which had arisen spontaneousiy in a  C3H female 18 yr previously, and 
had been transplanted every 6 wk. The remaining animals were similarly challenged 4 wk after 
treatment.  The development of the tumors was  observed for 50 days after challenge. The 
results are shown in Tables VIII A and VIII B. 
TABLE VII 
Effect of Pretreatment with MER on the Devdopment of Isografls of a Spontaneous Mammary 
Carcinoma in Rill Mice* 
Treatment of animals in 
0.5 cc, i.p.  No. of animals 
Cumulative No. of animals with palpable tumors at 
following intervals after implantation, ~vk 
5  9  13  17 
Saline  15  5  7  7  7 
MER, 0.5 mg  15  0  0  0  2 
* See text for experiment details. 
It  is  seen  from  Tables  VIII  A  and  VIII  B  that  pretreatment  with  MER 
succeeded  in  retarding  significantly the  development  of the  challenge  tumors 
implanted after both time intervals. 
Effect of Treatment  with MER on  the Growth of Established  Implants  of the 
Osteogenic Sarcoma.-- 
C3I-If males were given single subcutaneous implants of the osteogenic sarcoma described 
above. 2 and 7 days after implantation, the animals were treated with either 0.3 or 0.6 mg of 
MER in 0.5 cc of saline, or with saline alone. 20 animals were included in each group, half the 
animals receiving treatment by the intraperitoneal route, the other half by the subcutaneous 
one. All animals were observed for 51 days after implantation. The results are shown in Tables 
IXA  and  IXB. 
As is seen from Tables  IX  A  and  IX  B,  initiation  of treatment  with MER 
by either  the  intraperitoneal  or the  subcutaneous  routes after implantation  of 
isografts  of the  osteogenic sarcoma  was  still effective  in  bringing  about  some 
retardation  of the development of the tumors. 
Effect of Pretreatment  with MER and Other BCG Preparations on the Growth 
of Isografls  of a Methylcholantkrene-Induced  Fibrosarcoma in BALB/c Mice.-- 
BALB/c females were given single intraperitoneal injections of one of the following in 0.5 
cc of saline: living BCG; phenol-killed BCG, 0.5, 1.0, or 1.5 rag; MER, 0.5 or 1.0 mg; or saline 
only. Each group contained 8 to l0 animals. 3 wk later, the animals were challenged with a 
single subcutaneous implant of a  fibrosarcoma induced in a young adult BALB/c female by i 
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intramuscular injection of 3-methylcholanthrene. The tumor was in its first transplant genera- 
tion. The tumor developed very rapidly, and the animals were maintained until death. Table 
X shows the calculated volumes of the tumors 13 days after implantation (tumor volumes at 
later intervals are not shown because many of the animals died in the 3rd and 4th wk), and 
the mean and median survival times. 
It is evident from Table X  that the tumor isografts developed more rapidly 
in the groups treated with any of the BCG preparations. It has already been 
observed that direr immunization against isografts of spontaneous mammary 
carcinomas, i.e. by means of tumor cell preparations, can result in either height- 
ened  resistance  or  enhancement  of  tumor  growth,  and  evidence  has  been 
brought forward to indicate that both effects may be based on immunological 
mechanisms  (22,  26,  41):  Heightened  resistance  appears  to  result  when  the 
increment  in  cellular  reactivity is  more pronounced,  heightened  susceptibil- 
ity  when  the  humoral  response is  more  significantly  enlarged.  The  present 
observation that  tubercle bacillus  substances  can enhance  the  rate of tumor 
development  might,  accordingly,  also  have  an  immunological  explanation. 
It is of interest that living BCG, which usually proved inferior to MER and 
phenol-killed tubercle bacilli in eliciting heightened tumor resistance was here 
less  effective than  the  killed preparations  in  enlarging  tumor  susceptibility. 
It is also to be noted that more rapid growth of the tumors was directly cor- 
related with a  decreased survival time of the animals after tumor challenge. 
In  the  experiments  described  above,  a  slowing  of  tumor  development  was 
always accompanied by an increase in survival times. Longevity after tumor 
implantation can probably be viewed, therefore, as a function of tumor growth 
rate; and the effect of MER and other BCG preparations in prolonging life 
after challenge with most of the tumors here studied probably cannot be taken 
to reflect merely a  heightened resistance against secondary microbial disease. 
It seemed possible that the phenomenon of enhancement of tumor growth 
brought  about  in  this  experiment  by pretreatment  with  BCG  preparations 
might  occur  only  vis-a-vis  tumors  induced  by  a  hydrocarbon  carcinogen. 
Further  investigation revealed, however, that  enhancement of tumor growth 
by MER is also seen occasionally with spontaneous tumors. This is illustrated 
in the following experiment. 
Effect of Pretreatment with MER on the Growth of Isografts  of a Spontaneous 
Fibrosarcoma in DBA/2 Mice.-- 
DBA/2 females were given a single intraperitoneal injection of 0.5 mg of MER or of 0.5 ce 
of saline; 15 animals were treated with the MER and 13 with saline only. 25 days later,  the 
animals were challenged with a single subcutaneous implant of a first generation transplant 
of a fibrosareoma  which had arisen spontaneously in a multiparous DBA/2 breeding female. 
This tumor developed very slowly; the animals were maintained for 320 days after challenge. 
Tumor development was considerable more rapid in the mice treated with MER. In Table 
XI there are shown the calculated tumor volumes 2 months after implantation, and the cumu- 
lative numbers of animals dead with large tumors at intervals after tumor challenge. .° 
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The  results  show  that  enhancement  of  tumor  growth  may  be  elicited  by 
treatment  with MER  prior  to  implantation  of a  spontaneous  as  well as  of a 
carcinogen-induced neoplasm. 
Effect of Pretreatment with MER and Living BCG on the Growth of Isografts 
of a Spontaneous Myeloid Leukemia in C57Bl Mice.-- 
Although MER appeared to be more effective than living BCG in raising the resistance of 
mice against isografts of most of the tumors tested, living BCG proved capable of eliciting 
resistance against one tumor, a spontaneous myeloid leukemia in C57B1 mice, which proved 
TABLE XII 
Survival of C57Bl Mice Follougng Implantation of an Isogenic Mydoid Leukemia* 
Cumulative No. dead at following intervals after tumor 
challenge,$ wk 
Treatment of animals in 0.5 cc 
6  7  8  9110113 
b 
Route of treatment: intraperitoneal 
Saline  3  10  15  17  17  20 
Living BCG, 1:25 dilution  0  1  3  6  11  17 
MER, 0.3 mg  2  3  7  13  18  20 
MER, 0.6 mg  3  7  10  16  19  20 
Route of treatment: subcutaneou~ 
Saline  1  6  14  17  19  20 
Living BCG, 1:25 dilution  0  1  3  5  10  16 
MER, 0.3 mg  0  5  8  13  15  19 
MER, 0.6 mg  2  6  8  10  16  20 
* See text for experimental details. 
20 animals per group. 
refractory to pretreatment with MER. This observation was made in the following experi- 
ment: 
C57Bl males were given single intraperitoneal or subcutaneous injections of living BCG, 
0.3 or 0.6 mg of MER, or saline only. Each treatment group contained 20 mice. 40 days after 
the injections,  the  animals were challenged subcutaneously  with a  fragment  of a  myeloid 
leukemia which had arisen in a female animal 5 yr previously, and was now in the 47th trans- 
plant generation. The animals were maintained for 13 wk after challenge. Table XII shows the 
mean and median survival times of the animals in each group. 
It is seen from Table XII  that pretreatment  with riving BCG  by either the 
intraperitoneal  or the  subcutaneous  route  prolonged  significantly the survival 
times of  C57B1  mice challenged  with a  myeloid leukemia,  and  that  pretreat- 
ment  with MER  exerted no,  or only a  very slight,  protective  effect. DAVID W. WEISS, ROSE S. BONIKAG, AND  PATRICIA LESLIE  1061 
DISCUSSION 
The  findings here  presented  show clearly that  the  heterologous immuno- 
genicity  of  MER  is  not  limited  to  effects manifested  towards  pathogenic 
microorganisms, but is also exerted vis4-vis  isografts of neoplastic tissue. 
The  results  which were  obtained with new or  recently arisen  tumors  are 
more suggestive of immunological reactions directed at the neoplastic condi- 
tion  of  the  implanted  tissues  than  are  findings  derived  from  experiments 
in which the challenge tumors, albeit of isogenic origin, have been transplanted 
for many generations.  Isogenic drift within inbred strains of animals occurs 
not infrequently over long periods of time, and the genetic characteristics of a 
group of test animals may differ considerably from that of a tumor which had 
arisen in the strain many generations previously. Moreover,  the loss  of iso- 
antigens upon repeated passage of tumor cells has been well documented (e.g. 
reference 45). The resulting changes of the cell surface may affect acceptability 
of the cells by "isogenic" animals for nonimmunological reasons (46), and also 
for immunological ones not associated directly with the neoplastic nature of the 
tissue: The loss of some transplantation antigens from the surface of cells may 
well  result  in  the  exposure  of  other,  weak  transplantation  antigens  whose 
nonisogenicity within a  supposedly isogenic population may have  gone  un- 
detected.  The  phenomenon of "antigenic diversion" in  transplanted  tumors 
(47),  including the appearance of "fetal" antigens (48),  has also been shown. 
Moreover, it is not unlikely that clones of ceils passaged repeatedly in animals 
or in tissue culture may acquire new antigenic characteristics as a  manifesta- 
tion of the physiological consequences of a  very artificial existence, and not 
necessarily as a  manifestation of the neoplastic state as such. Continued pas- 
sage of cells must also result in the selection of clones possessing physiologic 
and  morphologic  characteristics  favored by the  conditions of the  passages, 
and these  are  likely to  be  dissimilar to  those prevailing when the  cells  are 
finally tested for ability to grow in a test host; it cannot be assumed, therefore, 
that long-passaged cells  bear a  close  biological resemblance to populations of 
neoplastic cells newly arisen in the autochthonous host. It is thus significant 
that MER could evoke heightened resistance against first transplant genera- 
tion tumors as well as against neoplasms carried for many generations in iso- 
genic hosts. 
The MER fraction was usually, but not always, more effective in eliciting 
increased resistance against tumors than were living BCG and the other tu- 
bercle  bacillus fractions,  thereby confirming the  high heterologous immuno- 
genicity displayed by this moiety against pathogenic bacteria (2).  It was clear 
from this, and from similar, unpublished studies, that treatment with MER, 
as well as with the other BCG substances, produces different effects vis-a-vis 
the  different  tumors  tested,  eliciting  various  degrees  of  resistance  against 1062  I{ETEROLOGOUS  TMMUNOGENICITY.  II 
many,  3 producing  enhanced  susceptibility towards  a  few,  and  occasionally 
exerting  no  effect.  The  importance  of  the  experimental  conditions--dosage 
and  route  of  administration  of  the  tubercle  bacillus  substance,  treatment- 
challenge interval, and others--was again (2)  indicated in these studies. 
It  will be  shown in  subsequent  communications that  quantities  of MER 
much in excess  of the optimal protective dose sometimes elicit enhancement 
rather  than  heightened  resistance  towards  spontaneous  mouse  mammary 
tumors in situ. It is possible,  therefore, that the enhanced growth of tumor im- 
plants  which  is  occasionally elicited  by  pretreatment  with  MER  similarly 
results from administration of too large a quantity, and that resistance would 
be  evoked against the tumors if smaller amounts of the activator were em- 
ployed. If this can be shown to be the case,  MER could be considered as a 
general stimulator of resistance against the  development of tumor isografts, 
provided  the  appropriate  dosage  is  administered. 
SUMMARY 
A  methanol-insoluble residue  (MER)  of phenol-killed attenuated  tubercle 
bacilli  (BCG),  which has been reported previously to  be capable of evoking 
heightened resistance to infection with antigenically unrelated microorganisms, 
was found to affect as well the resistance of highly inbred mice against tumor 
isografts. 
In most instances, the MER evoked heightened resistance against the tumor 
implants, but heightened susceptibility was the effect induced against two of 
the tumors tested, and no effect was elicited against one neoplasm. It is sug- 
gested that the  heightened susceptibility occasionally produced by pretreat- 
ment with MER may also be of immunological nature, i.e.  immunological en- 
hancement. 
Treatment  with  MER  was  more  effective when  administered  some  time 
before tumor challenge than when given simultaneously with, or after, tumor 
implantation. The protective effects manifested against some tumors were of a 
high order, a  significant number of animals rejecting the neoplastic implants, 
and  were  displayed  even  when  several  months  elapsed  between  treatment 
and challenge. 
Living BCG and intact phenol-killed bacilli also evoked heightened resist- 
ance against some of the  tumors tested,  and in one experiment living BCG 
proved  effective whereas MER did not.  On  the  whole, however,  MER was 
the most active (and least toxic, as shown previously) of the several tubercle 
bacillus preparations tested. 
MER elicited heightened reactivity against first transplant generation tu- 
a  The protective effect of MER has also been observed recently by Old against a murine 
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mors as well as against tumors maintained for considerable periods of time by 
repeated animal passage, and against spontaneously arising as well as against 
induced  neoplasms.  The  experimental parameters  necessary to  demonstrate 
maximal effects varied somewhat from tumor to tumor. In general, however, 
single intraperitoneal injections of small  quantities  of MER,  of the order of 
0.25  to  1.0  mg,  afforded the  best  protection. 
The authors acknowledge with gratitude the interest and valuable advice of Dr. K. B. 
DeOme; the skiUftd technical assistance of Mr. James Parks, Mrs. Marion Johnson, and Miss 
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